Polypharmacy: A Review of Adverse Drug Reaction, Interaction and Mitigation

Abstract

Polypharmacy, which is defined as the concurrent use of multiple medications, is increasingly popular because older adults must manage multiple chronic conditions. Polypharmacy seeks solutions for complex health issues. However, polypharmacy is in fact associated with a heightened risk for adverse drug reactions, drug-drug interactions and also diminished therapeutic efficacy. This review puts together present data on the harmful results from polypharmacy. It stresses the impact from polypharmacy on pharmacology and patient safety. These adverse effects are supported by pharmacokinetic alterations with aging affecting drug absorption, distribution, metabolism, and excretion, and pharmacodynamics changes influencing drug-receptor interactions. The possibility of drug-drug interactions rises when patients use many drugs and drug actions get better or worse, while adverse drug reactions risk increases, and adverse drug reactions may cause increased healthcare costs plus hospitalization. Polypharmacy has consequences that are particularly pronounced in older populations for studies indicate the number of medications and adverse drug reactions correlate greatly. A study found adverse drug reactions were three times more frequent among people on polypharmacy than among those on fewer medications. Gastrointestinal disturbances and drowsiness are common adverse drug reactions of polypharmacy. Fatigue can be another common adverse drug reaction. Mitigation strategies include reviews of medication on a regular basis, they de-prescribe unnecessary medications, medicine approaches are personalized, patients are educated, coupled with clinical decision support systems being implemented. The interventions seek to lower the risk for adverse outcomes as well as improve medication adherence via optimizing pharmacotherapy. In conclusion, while polypharmacy is often necessary for managing complex health conditions, its associated risks necessitate vigilant monitoring and management. Adopting a comprehensive, patient-centred approach can mitigate the adverse effects of polypharmacy and improve patient safety and quality of life. This abstract provides a concise overview of the review article, highlighting the key aspects of polypharmacy's adverse effects and strategies for mitigation.

Keywords

Introduction

Given the rising drift of persons over the age of 65 worldwide, polypharmacy is a getting more current in aged grown-ups. Examining the description as it appears in a standard medical wordbook reveals that the word “poly” is deduced from the Greek word meaning further than one and that “drugstore” pertaining to the Greek word for medicine “pharmakon”1. Polypharmacy, outlined as the concurrent use of multiple specifics, is getting a decreasingly common miracle, particularly in aged grown-ups and individualities with multiple habitual conditions. While the use of multiple specifics can be clinically necessary to manage complex health conditions, it is not without its pitfalls. Polypharmacy is nearly associated with adverse medicine responses, medicine- medicine relations, lowered remedial efficacity, and indeed increased mortality. As the number of specifics increases, so does the eventuality for these dangerous goods, which may compromise patient safety and well- being. This review explores the adverse goods of polypharmacy in pharmacology, pressing its mechanisms, consequences, and strategies for mollifying its risks2. For this description, specifics that are not indicated, not effective, or constitute a remedial duplication would be considered polypharmacy. Although this description is more clinically applicable, it does bear a clinical review of drug rules. This review will begin with information about the frequence and types of specifics taken by aged grown-ups with polypharmacy. This section will also punctuate the frequence and types of gratuitous medicines as well. The coming section will detail the epidemiology of adverse health issues performing from polypharmacy. Following this, substantiation from randomized, controlled intervention trials that included aged grown-ups with polypharmacy showing how drug use can be bettered will be presented. We’ll also finish with an expert opinion and conclusion sections³.

Objectives:

1. To Understand the pharmacokinetic and pharmacodynamics alteration: To explore pharmacokinetic changes and pharmacodynamics changes occurring with aging and how these may enhance the risks of polypharmacy.

2. To gauge the prevalence of polypharmacy among older adults and the correlates to the occurrence of adverse drug reactions and drug-drug interactions

3. Study some common Adverse drug reactions: To extrapolate adverse drug reactions that are usually observed with polypharmacy, such as gastrointestinal disturbances, drowsiness, and fatigue.

4. Assessment of mitigation strategies: To determine the efficacy of present mitigation strategies in minimizing risks associated with polypharmacy, which include regular medication review, de-prescribing unnecessary medications, personalized medicine, educating patients, and applying clinical decision support systems.

5. To recommend measures geared towards a comprehensive, patient-centered methodology of polypharmacy management for aged people with the intent of promoting patient safety and quality of life.

1. Mechanisms Behind Adverse Effects of Polypharmacy

1.1 Pharmacokinetic Interactions

The word pharmacokinetics is used to name the series of processes that include the absorption, distribution, metabolism, and excretion of drugs. Though very rarely, polypharmacy causes changes in these areas, raising the incidence of adverse effects. Aging, generally common in polypharmacy cases, causes physiological changes that affect the pharmacokinetics of drugs. For example:

1. Absorption: Changes in gastric pH and motility accompany aging, and these changes can affect the absorption rate of drugs. For instance, proton pump inhibitors (PPIs) increase gastric pH, thereby impairing the drug absorption of substances that require an acidic environment, such as iron and calcium supplements ³.
2. Distribution: Elderly people will have comparatively less lean body mass and will have more body fat, whereas lean body mass and body fat composition of a drug exert volume of distribution on lipophilic and hydrophilic drugs, respectively. Based on this difference, concentration levels of drugs in the bloodstream could be affected ³.
3. Metabolism: The liver is an important organ in the metabolism of drugs, while ageing results in functional decline and slow drug metabolism. Medications metabolized by the liver, such as warfarin or antihypertensive drugs, might build up to induce toxicity ³.
4. Excretion: In connection with aging, renal function also decreases, which decreases drug excretion, especially those drugs depending on renal clearance. The potential consequence would be the accumulation in the body of drugs such as digoxin and NSAIDs, and the increment of toxicity risk ³.

1.2 Pharmacodynamics Interactions

Pharmacodynamics is basically the physiological effect of the drug on the organism, along with its mode of action, side effects, etc. Polypharmacy may result in drug interactions or interferences, which can be synergistic or antagonistic in nature, thus possibly interfering with the end result expected from the patient:

1. Synergistic Interaction:

When two or more drugs are work together such that the combined effect of the two drug is larger than the sum of their independent effects is termed a synergistic interaction. This is a very important phenomenon encountered in clinical practice, drug development, and toxicology, as enhancement in either therapeutic benefits or adverse effects could take place, depending on the particular matter at hand ^4,5.

• Pharmacodynamic Synergism.

This relates to their interaction at the level of drug effects on the body. Synergism might arise when two drugs target a similar physiological system or target somewhat different systems that then converge to cause a magnified effect. This type of synergy may not necessarily alter plasma concentrations of the drugs involved but would instead try to magnify the clinical synergistic effect^5,6.

• Pharmacokinetic Synergism.

Here, one of the drugs modifies the absorption, metabolism, or excretion of another thereby leading to atypically high levels of the active agent⁷.

Antagonistic Interactions:

An antagonistic interaction occurs when the effect of one drug is reduced or completely blocked by another. This can result in a total therapeutic failure or can be intentionally used to counteract toxic effects or overdose. Antagonism is a pharmacodynamics interaction, meaning it relates to drug effects on the body, not necessarily their concentrations.

Types of Antagonism:

• Chemical Antagonism.
• Pharmacokinetic Antagonism.
• Receptor (Pharmacological) Antagonism.
• Physiological Antagonism⁸.

2. Consequences Of Polypharmacy

2.1. Adverse medicine responses:

 In polypharmacy, adverse medicine responses are a major concern. Age- related changes in pharmacokinetics and pharmacodynamics, along with comorbidities that bear the use of multiple specifics, make aged grown-ups more vulnerable to adverse medicine responses. According to a study, the threat of hospitalization from adverse medicine responses increases with polypharmacy, and the threat increases as the number of specifics increases. The most frequent adverse medicine responses associated with polypharmacy are cardiovascular events, renal dysfunction, gastrointestinal diseases, and cognitive impairment⁹.

2.2. Drug-drug Interactions (DDIs):

One of the main causes of DDIs, which can have serious clinical impacts, is polypharmacy. By affecting immersion, metabolism, or excretion, DDIs can change a medicine’s pharmacokinetics. For illustration, taking aspirin along with warfarin may consolidate the anticoagulant goods of warfarin, raising the threat of bleeding Likewise, the use of substances that block the cytochrome P450 enzyme system, like grapefruit juice or some antifungal medicines, can raise serum situations of substances that are these enzymes' substrates, raising the possibility of toxicity¹⁰. 

2.3. Increased Hospitalizations and Mortality:

The numerous studies have shown the link between polypharmacy and an advanced threat of death and hospitalisation. A regular study revealed that polypharmacy was linked to a 30 increased threat of hospitalization owing to drug- related problems including ADRs and DDIs. also, polypharmacy makes it more delicate to control cases' health, which could lead to infelicitous medicine (use and drug non adherence, both of which could beget negative health effects¹¹.

2.4. Reduced drug Adherence: Cases might find it delicate to control their medicine schedules as further specifics are specified. In polypharmacy, well- proved problems include drug non adherence, which this can beget. Poor compliance is caused by all three complicated medicine schedules, drug prices, and side goods. Ignoring specified medicines can aggravate current medical issues and beget further negative effects¹².

3. Risk Factors for Polypharmacy

Several factors contribute to the increasing prevalence of polypharmacy, particularly in older adults:

1. 1. Chronic Diseases:

Patients with several chronic diseases including hypertension, diabetes, and cardiovascular disorders usually need drugs from several therapeutic categories, hence raising the possibility of polypharmacy⁹.

1. 2. Age:

Aging is linked to more frequent comorbidities, polypharmacy, and greater medication use to control these conditions. Changes in organ function related to age also raise the likelihood of negative effects from several drugs¹³.

1. 3. Inadequate Medication Review:

In most clinical practice, drugs are prescribed without scrutinizing the existing drug therapy of the patient, leading to drug interactions, ADRs, and unnecessary drug prescriptions. In most clinical practice, drugs are prescribed without scrutinizing the existing drug therapy of the patient, leading to drug interactions, ADRs, and unnecessary drug prescriptions¹⁰.

4. Mitigation Strategies for Polypharmacy-Related Risks

 4.1. Structured and Regular Medication Review.

One of the main strategies to control polypharmacy is regular and organized medication reviews, especially in elderly and chronically ill patients. These reviews entail assessing all prescribed, over-the-counter (OTC), and herbal medications for indication, dose, efficacy, and safety. Pharmacists, primary care physicians, or geriatricians usually conduct these reviews to detect:

• Unnecessary or redundant drugs.
• Drugs with adverse interactions.
• Drugs with better alternatives¹⁴.

4.2. Deprescribing.

Deprescribing is the systematic and supervised reduction or cessation of medications that are no longer of benefit or potentially harmful. It aims to enhance quality of life and minimize polypharmacy-related risks. Deprescribing involves.

• Clinical judgment.
• Patient consent.
• Individualized risk-benefit analysis¹⁵.

4.3. Use of Clinical Decision Support Systems (CDSS).

Computerized prescribing systems with built-in CDSS identify potentially inappropriate medication, drug interactions, and contraindications in real-time. These systems:

• Warn prescribers of potential risks
• Recommend dose changes based on renal/liver function
• Incorporate patient-specific factors (age, comorbidities, lab values)¹⁶.

4.4. Use of Screening Tools: Beers Criteria and STOPP/START.

A number of evidence-based tools have been created to help clinicians identify high-risk medications:

• Beers Criteria (American Geriatrics Society): Provides lists of potentially inappropriate medications in older adults.
• STOPP/START Criteria (Screening Tool of Older People's Prescriptions): Evaluates both potentially inappropriate medications (STOPP) and under-prescribed medications (START)¹⁷.

4.5. Multidisciplinary Team Approach.

Treating polypharmacy is enhanced by a team-based approach with:

• Physicians (to prescribe and monitor)
• Pharmacists (to check for interactions and duplications)
• Nurses (to supervise administration and side effects)
• Geriatricians or specialists (in complicated cases)¹⁸.

4.6. Patient Education and Shared Decision-Making.

Informing patients about:

• The purpose of their medications.
• Potential side effects.
• Significance of adherence ¹⁹.

4.7. Reduction of High-Risk Drug Use.

Some drug classes have increased risk profiles in elderly or multiply comorbid individuals. These are:

• Benzodiazepines
• Anticholinergics
• NSAIDs
• Hypoglycaemics
• Long-acting sulfonylureas

4.8. Pill Organizers and Medication Synchronization.

• Simplistic organizational methods such as:
• Pill boxes/blister packs
• Refill synchronizing dates
• Medication calendars

4.9. Regular Monitoring and Follow-Up.

Following any change in medication or deprescribing, follow-up is necessary to:

• Monitor withdrawal effects
• Evaluate symptom control
• Reinforce compliance

4.10.  Policy-Level Interventions.

Healthcare systems can facilitate polypharmacy risk reduction by:

• Funding pharmacist-provided medication therapy management (MTM) programs
• Reimbursing time for medication review
• Adopting national deprescribing guidelines
• Facilitating interoperability of electronic health records (EHRs) for collective prescribing.

DISCUSSION:

The results of this review highlight the multifaceted nature of managing polypharmacy in older adults. The higher incidence of polypharmacy is linked with a greater rate of ADRs and DDIs, which result in negative health consequences and higher healthcare expenditures. The aging-related changes in pharmacokinetics and pharmacodynamics create additional medication management challenges, making it important to take a prudent and personalized approach to prescribing. Mitigation measures, including deprescribing and regular medication review, are critical in reducing the harms of polypharmacy. Patient education and patient involvement in decision-making can improve outcomes and adherence. Implementation of clinical decision support systems in practice can offer healthcare professionals useful tools to optimize pharmacotherapy and minimize the risk of adverse events.

CONCLUSION:

Although polypharmacy is frequently unavoidable in the management of complicated illnesses in older persons, its attendant risks must be closely monitored and managed. Regular medication review, deprescribing of inappropriate medications, and clinical decision support systems can prevent the harmful consequences of polypharmacy. Prioritizing patient safety.

REFERENCES

1. [May 2, 2013] Meriam Webster Medical Dictionary. At http://www.merriam-webster.com/ MedlinePlus/polypharmacy.
2. McKean, S., Ross, J., Dressler, D. D., Brotman, D., & Ginsberg, J. (2011). Principles and practice of hospital medicine. McGraw Hill Professional.
3. Ayalon, L., & Tesch-Römer, C. (2020). Contemporary Perspectives on Ageism.
4. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. [Internet]. 2003 [Acesso 28 jul 2015]; 289(9):1107-16. Disponível em: http://jama. jamanetwork.com/article.aspx?articleid=196099.
5. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. [Internet]. 2009 [Acesso 12 mar 2016];180(7):713-8. doi: 10.1503/cmaj.082001.
6. Caira, M. R., & Ionescu, C. (2006). Drug metabolism: Current Concepts. Springer Science & Business Media.
7. D’Arcy, P. F., McElnay, J. C., & Welling, P. G. (2012). Mechanisms of drug interactions. Springer Science & Business Media.
8. Fox, S. C. (2014). Remington Education Pharmaceutics. Pharmaceutical Press.
9. Capasso, F., Gaginella, T. S., Grandolini, G., & Izzo, A. A. (2012). Phytotherapy: A Quick Reference to Herbal Medicine. Springer Science & Business Media.
10. Schmiedl, S., et al. (2014). Polypharmacy in elderly patients: a challenge in pharmacotherapy. European Journal of Clinical Pharmacology, 70(6), 711-718
11. Tobin, M., et al. (2015). Benzodiazepine and opioid co-prescription and the risk of overdose: a systematic review. Journal of the American Medical Association, 313(15), 1570-1580.
12. Patel, R., et al. (2018). Polypharmacy and its impact on elderly patients. American Journal of Geriatric Pharmacotherapy, 16(5), 377-385.
13. Bauer, M. (2014). Polypharmacy: A Critical Review. International Journal of Clinical Pharmacy, 36(1), 64-68.
14. Muench, J., & Hamer, A. M. (2010). Adverse effects of antipsychotic medications. American Family Physician, 81(5), 617-622.
15. Hill-Taylor, B., Sketris, I., Hayden, J., Byrne, S., O’Sullivan, D., & Christie, R. (2013). Application of the STOPP/START criteria: A systematic review. Journal of Clinical Pharmacy and Therapeutics, 38(5), 360–372..
16. Reeve, E., Gnjidic, D., Long, J., & Hilmer, S. N. (2015). Systematic review of the emerging definition of deprescribing. British Journal of Clinical Pharmacology, 80(6), 1254–1268.
17. Ranji, S. R., Rennke, S., & Wachter, R. M. (2014). Computerized provider order entry with decision support to improve medication safety: A narrative review. BMJ Quality & Safety, 23(9), 773–780.
18. O'Mahony, D., O'Sullivan, D., Byrne, S., O'Connor, M. N., Ryan, C., & Gallagher, P. (2015). STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age and Ageing, 44(2), 213–218.
19. Garfinkel, D., & Mangin, D. (2010). Feasibility study of a systematic approach for discontinuation of multiple medications in older adults. Archives of Internal Medicine, 170(18), 1648–1654.